Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Diffuse large B-cell lymphoma (DLBCL) is the major type of aggressive B-cell lymphoma. High-grade B-cell lymphoma (HGBCL) with MYC/BCL2 double-hit (DH) represents a distinct entity with dismal prognosis after standard immunochemotherapy in the current WHO lymphoma classification. However, whether TP...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Cancer Res
Main Authors: Deng, Manman, Xu-Monette, Zijun Y., Pham, Lan V., Wang, Xudong, Tzankov, Alexandar, Fang, Xiaosheng, Zhu, Feng, Visco, Carlo, Bhagat, Govind, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Parsons, Benjamin M., Hagemeister, Fredrick, van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Xu, Bing, Liu, Phillip, Young, Ken H.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2020
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092941/
https://ncbi.nlm.nih.gov/pubmed/33154093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-20-0466
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים